View source for Neonatal hemochromatosis

==Background==
*Neonatal hemochromatosis (NH) is a clinical syndrome of severe neonatal liver disease with extrahepatic iron deposition (siderosis).<ref name="Feldman2013">Feldman AG, Whitington PF. Neonatal hemochromatosis. ''J Clin Exp Hepatol''. 2013;3(4):313-320. doi:10.1016/j.jceh.2013.10.004</ref> Nearly all cases are caused by gestational alloimmune liver disease (GALD), a maternal-fetal alloimmune disorder in which maternal IgG antibodies cross the placenta, attack fetal hepatocytes, and activate complement-mediated destruction.<ref name="Feldman2013"/> NH/GALD is the leading treatable cause of neonatal acute liver failure and carries >90% mortality without treatment.<ref name="AASLD">Little Livers, BIG Problems! Gestational Alloimmune Liver Disease. ''AASLD Liver Fellow Network''. 2024.</ref> The emergency physician must recognize the pattern of liver failure at birth with massively elevated ferritin and AFP, initiate IVIG empirically, and arrange double-volume exchange transfusion and urgent hepatology/neonatology consultation.
* Not a hereditary hemochromatosis — despite the name, NH is an alloimmune disease, not a genetic iron storage disorder<ref name="Feldman2013"/>
*Incidence: approximately 4 per 100,000 live births in the US; extremely rare globally (<1 per 1,000,000)
*GALD accounts for ~95% of NH cases<ref name="Stanford">Neonatal Hemochromatosis. ''Stanford Medicine Children's Health''. 2024.</ref>

===Mechanism===
*Mother becomes sensitized to a fetal hepatocyte surface antigen (the specific antigen remains unidentified)
*Maternal '''IgG antibodies''' cross the placenta (actively transported from ~18 weeks gestation)
*IgG binds fetal hepatocytes → activates '''terminal complement cascade (C5b-9)''' → hepatocyte injury and death<ref name="Feldman2013"/>
*Massive hepatocyte loss → liver failure, congenital cirrhosis
*Secondary iron overload occurs because:
**Damaged hepatocytes release stored iron
**Impaired hepatic hepcidin production → unregulated iron absorption
**Iron deposits in extrahepatic organs (pancreas, myocardium, thyroid, salivary glands) in a pattern that spares the reticuloendothelial system (spleen, lymph nodes, bone marrow are not iron-laden — this distinguishes NH from transfusional iron overload)<ref name="Feldman2013"/>

===Recurrence risk===
* 80-95% recurrence in subsequent pregnancies — this is critical information for family counseling<ref name="GALD_recon">Gestational alloimmune liver disease reconsidered. ''World J Gastroenterol''. 2025.</ref>
*Maternal '''IVIG during pregnancy''' (weekly from 18 weeks gestation) reduces recurrence to 5-10% with nearly 100% healthy live births<ref name="Stanford"/>
*First affected pregnancy is ''not'' predictable; typically unrecognized until the affected neonate presents

==Clinical features==
===Presentation at birth or within hours===
*Most NH infants are symptomatic at birth or within the first hours of life — this distinguishes NH from most other causes of neonatal liver failure, which typically develop over days to weeks<ref name="Feldman2013"/>
* Liver failure at birth:
**Severe conjugated hyperbilirubinemia (total bilirubin may exceed 30 mg/dL)
** Profound coagulopathy (INR often >3; unresponsive to vitamin K)
** Hypoalbuminemia
** Hypoglycemia (impaired hepatic gluconeogenesis)
** Hyperammonemia
* Ascites and edema
* Hepatomegaly (liver palpable several cm below costal margin; may also be small if severe cirrhosis)
* Oliguria/renal failure (hepatorenal syndrome)

===Prenatal findings (may be reported in history)===
* Intrauterine growth restriction (IUGR)
* Oligohydramnios
* Hydrops fetalis (in severe cases)
* Stillbirth (NH should be considered in unexplained fetal demise)
*Prematurity (about half of NH infants are preterm)<ref name="Frontiers_GALD">Efficacy of IVIG/ET Therapy on GALD. ''Front Pediatr''. 2021;9:680730.</ref>

===Characteristic laboratory pattern===
The following constellation is highly suggestive of NH:
* Ferritin: massively elevated (typically >800 ng/mL; commonly 2,000-150,000+ ng/mL) — sensitive but not specific, as any severe liver injury elevates ferritin<ref name="Feldman2013"/>
* Transferrin: low but hypersaturated (saturation often >90-100%) — one of the most characteristic findings<ref name="Medscape_NH">Neonatal Hemochromatosis Workup. ''Medscape''. 2024.</ref>
* AFP: very high (typically 100,000-600,000 ng/mL — even higher than neonatal baseline)
* AST/ALT: disproportionately low (often <100 IU/L despite severe liver failure) — this is because there are so few viable hepatocytes remaining that transaminase release is minimal<ref name="Feldman2013"/>
* INR markedly elevated (often >3)
*Hypoglycemia, hyperammonemia, hypoalbuminemia, metabolic acidosis

==Differential diagnosis==
===Neonatal acute liver failure===
* [[Neonatal HSV|Neonatal herpes simplex (HSV)]] — the most important alternative diagnosis; start empiric acyclovir alongside IVIG while differentiating (HSV typically presents slightly later, days 7-14, and has markedly elevated AST/ALT, unlike NH)
* [[Tyrosinemia|Tyrosinemia type 1]] — very high AFP + coagulopathy (similar to NH); Fanconi syndrome distinguishes; urine succinylacetone is pathognomonic
* [[Galactosemia]] — after initiation of lactose-containing feeds; reducing substances in urine; ''E. coli'' sepsis
* Hemophagocytic lymphohistiocytosis (HLH) — fever, hepatosplenomegaly, pancytopenia, hyperferritinemia, hypertriglyceridemia; can closely mimic NH; soluble IL-2 receptor and NK cell activity help distinguish
* Hereditary fructose intolerance — after fructose/sucrose exposure
* Mitochondrial hepatopathy (DGUOK mutations, others)
* Bile acid synthesis defects
* Bacterial [[Sepsis|sepsis]]

===Key distinguishing features of NH===
*Liver failure present at or within hours of birth (most other causes present later)
*AST/ALT disproportionately low for degree of liver failure
* Extrahepatic siderosis (pancreas, heart, thyroid iron-laden on MRI) with splenic sparing
*Ferritin and transferrin saturation massively elevated

==Evaluation==
===ED workup===
* Hepatic panel: AST, ALT (expect disproportionately low), bilirubin (fractionate), albumin
* Coagulation studies: PT/INR, fibrinogen
* Ferritin: expect massively elevated (>800 ng/mL; commonly >10,000)
* Iron studies: serum iron, transferrin, transferrin saturation (expect >90%)
* AFP (alpha-fetoprotein): expect markedly elevated
* Blood glucose: frequent monitoring; anticipate hypoglycemia
* Ammonia
* BMP: electrolytes, creatinine (hepatorenal syndrome)
* CBC: thrombocytopenia (common)
* Blood cultures, urinalysis/urine culture — to exclude sepsis
* HSV PCR (blood and CSF if LP feasible) — '''must exclude HSV empirically'''
* Lactate

===Confirmatory testing for extrahepatic siderosis===
* Abdominal MRI (T2-weighted): the most useful diagnostic study<ref name="Medscape_NH"/>
**Demonstrates low T2 signal in liver and pancreas (iron-laden) with normal/preserved signal in spleen (reticuloendothelial sparing)
**Can also show iron in myocardium and thyroid
** Extrahepatic siderosis in pancreas + thyroid is diagnostic of NH
**Can be performed within hours of birth
* Buccal (minor salivary gland) biopsy:<ref name="Feldman2013"/>
**3-mm punch biopsy of lower lip mucosa (must include submucosal salivary glands)
**Prussian blue stain reveals hemosiderin in acinar epithelial cells
**Positive in approximately two-thirds of proven NH cases
**Minimally invasive; can be performed at bedside even with severe coagulopathy (bleeding controlled by local measures; FFP not required beforehand)
* Liver biopsy: generally avoided due to severe coagulopathy; if performed, shows hepatocyte loss, giant cell transformation, fibrosis/cirrhosis, hepatocyte siderosis with Kupffer cell sparing; C5b-9 immunostaining supports GALD diagnosis
*If either MRI or buccal biopsy demonstrates extrahepatic siderosis → diagnosis of NH is established<ref name="Feldman2013"/>

==Management==
===Immediate ED management===
* Give one dose of IVIG (1 g/kg IV) as soon as NH/GALD is suspected — '''do not wait for MRI or biopsy confirmation'''<ref name="AASLD"/>
**Mechanism: blocks complement-activating antibodies from continuing hepatocyte destruction
**Current expert recommendation: any neonate in liver failure should receive one dose of IVIG while GALD is being evaluated<ref name="Feldman2013"/>
* Start empiric IV acyclovir (20 mg/kg/dose every 8 hours) simultaneously — HSV disseminated disease is the most important alternative diagnosis and cannot be reliably excluded clinically; treat for both until testing clarifies
* Correct coagulopathy: FFP, cryoprecipitate (note: coagulopathy in NH is often refractory to vitamin K because it reflects synthetic failure, not vitamin K deficiency)
* Correct hypoglycemia: D10W infusion with frequent glucose monitoring
* IV fluids: cautious volume management (risk of fluid overload with ascites/edema)
* Broad-spectrum antibiotics if sepsis is in the differential

===Definitive treatment===
* Double-volume exchange transfusion (DVET):<ref name="GALD_case">Gestational alloimmune liver disease treated with exchange transfusion and IVIG. ''Pediatr Neonatol''. 2022;63(1):94-96.</ref>
**Purpose: physically removes circulating maternal IgG antibodies that are driving hepatocyte destruction
**Performed with twice the calculated blood volume
**Should be followed immediately by IVIG infusion
* IVIG (1 g/kg IV): given after DVET to block any remaining antibody-induced complement activation
**May require multiple doses (published cases describe 1-4 doses)
*This combination (DVET + IVIG) has improved survival from ~10-20% (historical) to 75% without liver transplant in the best-reported series<ref name="Feldman2013"/>
*'''Do NOT give mother's breast milk''' — maternal antibodies directed against neonatal hepatocytes may continue to pass through breast milk<ref name="AASLD"/>

===Liver transplant===
*Consider if patient fails to respond to IVIG ± DVET within days
*NH is a common indication for liver transplantation in the first 3 months of life
*INR recovery may take 4-6 weeks or longer after successful immunotherapy — treatment prevents ongoing immune injury but does not reverse damage already sustained<ref name="AASLD"/>

===Therapies of historical interest (largely replaced)===
* Antioxidant/chelation cocktail (vitamin E, selenium, N-acetylcysteine, prostaglandin E1, deferoxamine) — used before GALD mechanism was discovered; survival only 10-20%; no longer first-line<ref name="Feldman2013"/>

==Disposition==
* All suspected NH cases: NICU admission
* Immediate consultations:
**Neonatology (DVET, NICU management)
**Pediatric hepatology/GI (diagnosis confirmation, IVIG, transplant evaluation)
**Pediatric surgery/transplant center (early notification — emergent transplant may be needed)
* Transfer to a center with neonatal liver transplant capability if not available locally — do not delay IVIG while arranging transfer
* Communicate to the family:
**90% recurrence risk in future pregnancies
**Prenatal IVIG treatment is available and highly effective for preventing recurrence
**Refer to maternal-fetal medicine for future pregnancy planning

==See Also==
*[[Neonatal hepatitis]]
*[[Neonatal HSV]]
*[[Tyrosinemia]]
*[[Galactosemia]]
*[[Acute liver failure]]
*[[TORCH infections]]
*[[Hemochromatosis]]

==External Links==
*[https://pmc.ncbi.nlm.nih.gov/articles/PMC3940210/ J Clin Exp Hepatol — Neonatal Hemochromatosis (Feldman & Whitington, 2013)]
*[https://www.aasld.org/liver-fellow-network/core-series/clinical-pearls/little-livers-big-problems-gestational-alloimmune AASLD — Little Livers, BIG Problems: Gestational Alloimmune Liver Disease]
*[https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2021.680730/full Front Pediatr — Efficacy of IVIG/ET Therapy on GALD (2021)]
*[https://emedicine.medscape.com/article/929625-workup Medscape — Neonatal Hemochromatosis Workup]
*[https://www.stanfordchildrens.org/en/services/fetal-and-pregnancy-health/conditions/neonatal-hemochromatosis.html Stanford Children's — Neonatal Hemochromatosis]

==References==
<references/>

[[Category:Pediatrics]]
[[Category:GI]]
[[Category:Heme/Onc]]